Mutating Antibodies for Easier Drug-Conjugate Manufacturing
Scientists at Johns Hopkins University have engineered a general‑purpose antibody by mutating its fragment crystallizable (Fc) region, creating up to four new attachment sites for molecules such as drugs, dyes, or nanoparticles. Six precise Fc mutations enable consistent, site‑specific conjugation, addressing the heterogeneity that hampers antibody‑drug conjugate (ADC) manufacturing. The team demonstrated the platform by attaching fluorescent dyes and coating nanoparticles, showing reliable quantification of available sites and efficient cargo delivery into target cells. This tunable system could simplify ADC production and expand research applications.
Mixed-Reality Fermentation Simulator Preps Workforce
Mixed-reality platform BioSuite Virtual, created by Prism Immersive with BioMADE funding, delivers end‑to‑end fermentation training through over 40 interactive modules. The system blends virtual bioreactors with physical space, letting learners assemble, sterilize, inoculate, and monitor runs at their own pace....
Emerging Nanoreactors for Precision Disease Treatment: From Principles to Biomedical Applications
Nanoreactors—engineered nanostructures that emulate cellular compartments—are reshaping precision nanomedicine. By confining reactants, integrating synergistic catalytic sites, and responding to physiological cues, they dramatically accelerate therapeutic reactions and enable controlled drug release. Recent advances span organic, polymeric, and organic‑inorganic hybrids, showing...
Application of Hydrogel in the Capture and Detection of Circulating Tumor Cells
The review details how hydrogel‑based platforms are reshaping circulating tumor cell (CTC) capture and detection. Hydrogels provide a three‑dimensional porous matrix that enhances cell infiltration, biocompatibility that preserves CTC viability, and tunable chemistry for affinity‑driven targeting. By coupling these materials...
Medtronic Data Back Renal Denervation in the Long Term
Medtronic reported that two EuroPCR abstracts based on the global SYMPLICITY registry show its Symplicity Spyral renal denervation system delivers sustained blood‑pressure reductions over three years. One analysis of 787 patients with prior cardiovascular events recorded a 17.4 mmHg drop in office...
FDA’s Megha Kaushal ASGCT Talk: PFDD, Patient Voices, Decision-Making
At the 2026 ASGCT meeting, FDA Acting Deputy Director Megha Kaushal highlighted the agency’s Patient‑Focused Drug Development (PFDD) initiative, urging early integration of patient and caregiver input into cell and gene therapy trials. She emphasized that families’ lived‑experience data should inform...
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
Guardant Health announced FDA approval of Guardant360® Liquid CDx, the largest liquid‑biopsy panel on the market, featuring a 100‑fold expanded genomic footprint. The test merges genomic and epigenomic profiling from a single blood draw, delivering several‑fold higher circulating tumor DNA...
IntraBio Receives Regulatory Authorization to Begin Pivotal Phase III Trial of Levacetylleucine in CACNA1A-Related Disorders Across Participating Regions
IntraBio announced regulatory authorization to launch its pivotal Phase III trial of levacetylleucine (AQNEURSA) in CACNA1A‑related disorders across the United States, United Kingdom, European Union and Switzerland. The 12‑week, randomized, double‑blind, placebo‑controlled crossover study will be conducted at twelve multinational sites...
WVE-006 RNA Editing Therapy Achieves MZ-Like Phenotype in Alpha-1 Antitrypsin Deficiency Phase 1b/2a Trial
Wave Life Sciences reported that its investigational RNA‑editing drug WVE‑006 generated major‑variant alpha‑1 antitrypsin (M‑AAT) levels comparable to the protective heterozygous Pi*MZ phenotype in patients with homozygous Pi*ZZ AAT deficiency. The Phase 1b/2a RestorAATion‑2 trial showed 64%–59% of circulating AAT was...
EQS-News: GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
GeoVax Labs warned that the escalating Bundibugyo Ebola outbreak in Central Africa highlights the lack of licensed vaccines for less‑common Ebola strains. The company pointed to its Modified Vaccinia Ankara (MVA) platform, which has shown single‑dose protection against Zaire and...
FDA Approves Baxdrostat, First‑in‑Class Aldosterone Synthase Inhibitor for Hypertension
The U.S. Food and Drug Administration has approved baxdrostat, AstraZeneca's first‑in‑class oral aldosterone synthase inhibitor, as an add‑on treatment for adults whose hypertension remains uncontrolled despite existing therapy. The decision follows a Phase III trial that demonstrated statistically significant systolic blood‑pressure...
Ipsen’s Dysport Outlasts Botox in First Head‑to‑Head Spasticity Trial
Ipsen announced that its botulinum toxin product Dysport delivered significantly longer symptom control than rival Botox in the Phase IV DIRECTION trial, a randomized head‑to‑head study of 464 adults with upper‑limb spasticity across 72 sites in the U.S., France and Canada.
Annovis Bio Raises $175 Million in Share and Warrant Offering to Advance Alzheimer’s Drug Buntanetap
Annovis Bio disclosed a $175 million public offering of shares and warrants to finance the Phase 3 development of its Alzheimer’s candidate Buntanetap. The financing move coincided with a 5.4% drop in the company’s stock, reflecting market caution. Proceeds will support the...
Treating Pattern Hair Loss: How Close Are We?
VeraDermics’ oral minoxidil pill VDPHL01 cleared a pivotal phase 2/3 trial, showing a 30‑33 hairs/cm² increase in non‑vellus hair count versus 7.3 for placebo and coverage improvement in over 79% of participants. The extended‑release formulation reduces peak blood levels that have...
Scientists Found a Hidden Alzheimer’s Trigger and Shut It Down
Researchers at Indiana University identified the brain enzyme IDOL as a promising new target for Alzheimer’s therapy. Deleting IDOL from neurons in mouse models dramatically cut amyloid plaque buildup and lowered APOE levels, a key genetic risk factor. The findings...
Engineered Nanomaterials Optimize Delivery Barriers in Cancer Immunotherapy
A new review outlines how engineered nanomaterials can overcome delivery bottlenecks in cancer immunotherapy by matching material design to each step of the immunity cycle. It details active‑targeting ligands, intracellular escape mechanisms, and co‑delivery of antigens, adjuvants, mRNA or CRISPR...
Beam One-Ups Wave as Both Show Promise of Editing for AATD
Beam Therapeutics presented Phase 1/2 data for its DNA editor BEAM‑302, showing an 80% drop in mutated alpha‑1 antitrypsin (AAT) protein and lifting total AAT above the 11 µM protective threshold, with effects lasting 12 months. Wave Life Sciences reported its RNA editor...
AbbVie’s New Immunology Standard-Bearer Skyrizi Kneels to UCB’s Bimzelx in Psoriatic Arthritis
UCB’s Bimzelx outperformed AbbVie’s Skyrizi in a Phase 3 head‑to‑head trial for psoriatic arthritis, achieving 49.1% ACR50 versus 38.4% for Skyrizi at week 16. While Bimzelx also showed numerically higher minimal disease activity (43% vs 39.9%), the difference missed statistical significance. Skyrizi...
Ketamine‑Buprenorphine Regimen Cuts Suicide Ideation by 76% in Trial
Researchers reported that a single ketamine infusion followed by four weeks of low‑dose buprenorphine lowered suicidal ideation by 76% in adults with major depressive disorder, far surpassing the 43% reduction seen with placebo. The double‑blind trial, published in the American...
Topical Senolytic ABT-263 Boosts Wound Healing in Aged Mice by 43%
Researchers at Boston University demonstrated that a cream containing the senolytic ABT-263 removed aging skin cells and accelerated wound repair in elderly mice, achieving an 80% healing rate by day 24 versus 56% in controls. The finding points to a...
Relay Therapeutics Posts 60% Response in Phase 2 Trial of Zovegalisib for Rare Vascular Anomalies
Relay Therapeutics said 60% of evaluable patients achieved a volumetric response in its Phase 2 ReInspire trial of zovegalisib for PIK3CA‑driven vascular anomalies. The data, presented at the ISSVA World Congress, outpace Novartis' prior 11% response and could position the...
Airway Therapeutics CEO on Rethinking Bronchopulmonary Dysplasia Trials
Airway Therapeutics is advancing zelpultide alfa, an investigational biologic aimed at preventing bronchopulmonary dysplasia (BPD) in extremely preterm infants born between 22 and 27 weeks gestation. CEO Marc Salzberg highlighted the clinical and operational hurdles of neonatal trials, including limited...
DeepMind's Co‑Scientist AI Tackles Cancer Drug Discovery with Big‑data Analytics
Google DeepMind unveiled Co‑Scientist, a multi‑agent AI platform designed to accelerate biomedical research. In a pilot for acute myeloid leukemia, the system shortlisted 30 drug candidates, three of which showed promising activity in lab tests. The launch signals a new...
Colossal Biosciences Hatches Live Chicks From Fully Artificial Egg, Paving Way for Moa De‑Extinction
Colossal Biosciences announced that its newly engineered artificial egg successfully hatched live chicks, demonstrating a scalable platform for avian embryo development without supplemental oxygen. The breakthrough underpins the company’s South Island Giant Moa de‑extinction program and could reshape conservation biotech.
Canagliflozin - Another Top Longevity Drug
A small, exploratory randomized trial tested dapagliflozin, an SGLT2 inhibitor, in early‑stage Alzheimer’s disease. The primary endpoint—magnetic resonance spectroscopy measurement of brain N‑acetylaspartate—showed no significant difference versus placebo. Nonetheless, the drug markedly increased systemic glucose disposal, confirming its expected metabolic...
QIAGEN and NVIDIA Partner on AI Drug Discovery
Qiagen’s Digital Insights division will embed NVIDIA’s accelerated computing and BioNeMo platform into its bioinformatics suite, creating a graph‑based AI environment for drug discovery. The integration is designed to streamline target identification, biomarker discovery, and multi‑omics hypothesis generation for pharma...
BioMarin’s ENERGY 3 Trial of BMN 401 Meets One Co-Primary Endpoint
BioMarin Pharmaceutical announced that its Phase III ENERGY 3 trial of BMN 401 met one of two co‑primary endpoints, showing a statistically significant rise in plasma inorganic pyrophosphate (PPi) levels in children with ENPP1 deficiency through week 52. The trial failed to demonstrate any...
Proactivity for Drug Safety: A New Service or a New Mindset?
The letter argues that proactive drug‑safety surveillance cannot fix a system that approves drugs with insufficient benefit data and overlooks rare, severe harms. It cites historic delays in risk‑management actions for valproate and topiramate, noting that formal REMS were only...
Tuneable Peptide Biotech Parabilis Files IPO
Parabilis Medicines, the Cambridge‑based tuneable peptide biotech, filed a Nasdaq prospectus to raise roughly $100 million in an IPO under the PBLS ticker. The offering follows a $305 million private round and a multi‑billion‑dollar alliance with Regeneron, which contributed $50 million upfront and...
Eight Swedish Companies Spearheading the Country’s Biotech Scene in 2026
Sweden’s life‑science sector, now worth roughly $42 billion in turnover and employing over 52,000 people, is being propelled by eight standout biotech firms. Annexin Pharmaceuticals reported safety and early efficacy in a phase 2a ophthalmology trial, while Anocca raised $46 million to advance...
Lilly Snaps up Engage to Advance Non-Viral Genetic Medicines
Eli Lilly agreed to acquire Engage Biologics for up to $202 million in cash, adding the company’s non‑viral DNA delivery platform called Tethosome. The technology combines lipid‑nanoparticle shells with an mRNA‑encoded transport protein to move genetic payloads into cell nuclei without viral vectors....
Beyond Senolytics: Senoadaptive Drugs & Clinical Data on GPX4 Modulation (Dr. Marco Quarta, Rubedo)
In this episode, Dr. Marco Quarta, co‑founder and CSO of Rubedo Life Sciences, discusses the company’s breakthrough first‑in‑class GPX4‑modulating drug RLS1496, which has just reported preliminary Phase 1 basket‑trial data across multiple skin indications. He explains how Rubedo’s AI‑enabled single‑cell multi‑omics...
Efficacy of Ustekinumab Combined with Partial Enteral Nutrition in Crohn’s Disease
A retrospective cohort of 124 Crohn’s disease patients showed that adding partial enteral nutrition (PEN) to ustekinumab (UST) therapy markedly improved long‑term mucosal healing. At week 54, endoscopic remission was achieved in 71.05% of the UST + PEN group versus 50.00% with...
UCB Reports P-III (BE BOLD) Trial Data on Bimzelx in Active Psoriatic Arthritis
UCB disclosed Phase III BE BOLD trial results comparing its Bimzelx (bimekizumab) to AbbVie’s Skyrizi (risankizumab) in 553 adults with active psoriatic arthritis. The primary endpoint was met, with 49.1% of patients achieving an ACR50 response at week 16 versus 38.4%...
Reimagining Vaccine Development with AI
Traditional vaccine trials can take 5‑10 years, limiting response to emerging pathogens. AI‑driven adaptive designs and predictive analytics promise to shorten timelines, achieving 85‑90% outcome prediction accuracy versus 70‑75% for conventional models. By automating site selection, forecasting disease hotspots, and...
TMDX Poised for Massive Organ Transport Growth by 2032
I spent some quality time today with the $TMDX team at their HQ in Andover, MA. I’ll share some deeper thoughts over the next few days including my bear case, base case, bull case and super bull case for the...
BARDA Ships Experimental Ebola Antibody to Protect High‑risk Americans
BARDA is coordinating shipment of an experimental antibody treatment for potential use in high-risk Americans exposed to #ebola, HHS tells CNN While they didn't name the treatment, Mapp's MBP134 has shown activity in animal studies against Bundibugyo strain
Field-Ready Tool Identifies Rare and Zoonotic Parasitic Worms Missed by Standard Tests
Researchers at the University of Melbourne and UNSW have created a field‑ready diagnostic that uses Oxford Nanopore long‑read sequencing to profile the full community of parasitic nematodes in stool from humans and animals. Validation showed sensitivity and specificity comparable to...
Peer-Reviewed Paper Says Genetically Engineering Ticks to Spread Meat Allergies Is “Morally Obligatory"
A peer‑reviewed paper argues that genetically editing lone‑star ticks to spread alpha‑gal syndrome—a meat allergy—constitutes a moral bio‑enhancement. The authors claim the ticks could be engineered to carry the allergy, survive longer, and avoid other diseases, making meat consumption less...
Merck and Kelun‑Biotech’s Sac‑TMT ADC Cuts Death Risk in Phase III Endometrial Cancer Trial
Merck and China‑based Kelun‑Biotech announced that their TROP2‑directed ADC sacituzumab tirumotecan (sac‑TMT) met primary endpoints in the TroFuse‑005 Phase III trial, delivering statistically significant overall‑survival and progression‑free‑survival improvements versus physician‑chosen chemotherapy in 776 patients with advanced or recurrent endometrial cancer. The...
GeoVax Labs Raises $3 Million Private Placement, Emphasizes MVA Platform for Pandemic Preparedness
GeoVax Labs announced a $3 million private placement on May 19, 2026, and used the filing to stress the strategic value of its Modified Vaccinia Ankara (MVA) platform for rapid, scalable vaccine responses to emerging infectious threats. The financing will back ongoing development...
Startup Creates Embryos Using Lab-Grown Sperm
Paterna Biosciences announced it has successfully generated human sperm cells from stem cells in the laboratory and used them to fertilize oocytes, producing embryos. The breakthrough was demonstrated by co‑founder and CEO Dr. Alex Pastuszak, who explained the step‑by‑step protocol...
Kraig Biocraft Labs Creates Immortalized Silk Gland Cell Line
Kraig Biocraft Laboratories announced the creation of an immortalized silk gland cell line that could serve as the foundation for a next‑generation biotechnology platform. The cells exhibit strong proliferative capacity, stable serial passaging and robust long‑term viability, while delivering high...
Sustained Therapeutics – Presents Positive Phase 2 Data for ST-01 in Podium Presentation at the American Urological Association 2026 Annual...
Sustained Therapeutics presented Phase 2 data showing its ST‑01 polymer‑lidocaine formulation significantly reduced pain in men with chronic scrotal content pain (CSCP). At the 70 mg/mL dose, 67% of patients achieved a ≥2‑point pain reduction and 83% met clinical response criteria, far...
Why the Need to Expand Industry Focus Beyond Gene Editing Toward Scalable Cell Therapy Manufacturing?
Cell therapy developers are moving beyond pure gene‑editing breakthroughs to prioritize scalable manufacturing, according to Cellular Origins CEO Dr. Edwin Stone at the 2026 ASGCT meeting. The industry is integrating manufacturing feasibility into early‑stage development, evaluating multiple delivery platforms such...
Multi‑Agent AI Boosts Biomedical Discovery Across Diseases
A big day for multi-agent AI to accelerate biomedical discovery, hypothesis generation, designing experiments with proof points of new candidate drugs (cancer, fibrosis, macular degeneration, antimicrobial resistance, and more) 2 @Nature reports @GoogleDeepMind @FutureHouseSF https://t.co/u1EYvJ05VJ https://t.co/8DpAolom0F
Mentari Therapeutics Announces Merger with InMed Pharmaceuticals, Concurrent $290 Million Private Placement
Mentari Therapeutics, a biotech focused on migraine prevention, announced a merger with InMed Pharmaceuticals alongside a $290 million private placement. The financing round was led by Fairmount and featured investors such as a16z Bio + Health, Venrock, Wellington Management, and Blackstone...
Full-Life Technologies Secures $150 Million Series D to Scale Radiotherapeutics Platform
Full-Life Technologies closed a $150 million financing package—$110 million in Series D equity and $40 million in debt—led by Vivo Capital and a slate of strategic investors. The capital will accelerate its alpha‑emitting radiotherapeutics pipeline and bring a GMP‑grade manufacturing site in Belgium online,...
FDA Clears Genentech’s Tecentriq for ctDNA-Guided Adjuvant Bladder Cancer Therapy
Genentech announced FDA approval of Tecentriq and Tecentriq Hybreza as adjuvant therapy for muscle‑invasive bladder cancer patients with ctDNA‑detected minimal residual disease. The Phase III IMvigor011 trial showed a 36% drop in disease recurrence or death and a 41% reduction in...
CRISPR-Based System Targets RNA and Kills Cells on Demand
Scientists at Utah State University have engineered a CRISPR‑Cas12a2 system that reads a specific RNA transcript and triggers uncontrolled DNA shredding, killing the host cell. The enzyme reduced yeast colonies 134‑fold and stopped proliferation of HeLa cancer cells, even when...